Trial reportBritish journal of haematology2016
Genetic differences between paediatric and adult Burkitt lymphomas.
Trial report in British journal of haematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children.The New England journal of medicine · 2020Trial
- Next generation sequencing identifies novel gene alterations with potential prognostic relevance in pediatric cancer: a single-center study.The oncologist · 2026Article
- Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.Haematologica · 2023Article
- Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.Nature communications · 2022Article
- Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.Leukemia · 2022Article
- A novel prognostic index for sporadic Burkitt lymphoma in adult patients: a real-word multicenter study.BMC cancer · 2022Article
- The "Burkitt-like" immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.Virchows Archiv : an international journal of pathology · 2021Article
- Pediatric Lymphoid and Histiocytic Lesions in the Head and Neck.Head and neck pathology · 2021Review
- Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.Leukemia & lymphoma · 2020Review
- Burkitt lymphoma of the ovaries mimicking sepsis: a case report and review of the literature.Journal of medical case reports · 2018Article
- Paradoxical role of Id proteins in regulating tumorigenic potential of lymphoid cells.Frontiers of medicine · 2018Review
- Management of aggressive B-cell NHLs in the AYA population: an adult vs pediatric perspective.Blood · 2018Review
- Risk factors for Burkitt lymphoma: a nested case-control study in the UK Clinical Practice Research Datalink.British journal of haematology · 2018Article
- Age-related heterogeneity of Burkitt lymphoma.British journal of haematology · 2018Article
- Williams-Beuren Syndrome as a Potential Risk Factor for Burkitt Lymphoma.Frontiers in genetics · 2018Article
- Case Reports in Oncological Medicine Myoepithelioma: A New Rearrangement Involving theCase reports in oncological medicine · 2018Article
- Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.Haematologica · 2017Article
- Survival predictors of Burkitt's lymphoma in children, adults and elderly in the United States during 2000-2013.International journal of cancer · 2017Article
- Burkitt lymphoma in adolescents and young adults: management challenges.Adolescent health, medicine and therapeutics · 2017Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysregulation of MYC is the genetic hallmark of Burkitt lymphoma (BL) but it is encountered in other aggressive mature B-cell lymphomas. MYC dysregulation needs other cooperating events for BL development. We aimed to characterize these events and assess the differences between adult and paediatric BLs that may explain the different outcomes in these two populations. We analysed patterns of genetic aberrations in a series of 24 BLs: 11 adults and 13 children. We looked for genomic imbalances (copy number variations), copy-neutral loss of heterozygosity (CN-LOH) and mutations in TP53, CDKN2A, ID3 (exon 1), TCF3 (exon17) and CCND3 (exon 6). Young patients displayed more frequent 13q31.3q32.1 amplification, 7q32q36 gain and 5q23.3 CN-LOH, while 17p13 and 18q21.3 CN-LOH were only detected in adult BLs. ID3 mutations were present in all adult samples, but only in 42% of childhood cases. CCND3 and ID3 double-hit mutations, as well as 18q21 CN-LOH, seemed to be associated with poorer outcome. For the first time, we report different genetic anomalies between adult and paediatric BLs, suggesting age-related heterogeneity in Burkitt lymphomagenesis. This may explain the poorer prognosis of adult BLs. Additional studies are needed to confirm these results in the setting of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.